// App-Quantinova.ai

4039 : Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade (TRG) ≥3 in oesophago-gastric cancer (OGC).

Researchers

Presenter

  • Brindley Sonal Hapuarachi

Principal Investigators

  • Rebecca Lee

  • Adeel Khan

  • Laura Woodhouse

  • Valentinos Kounnis

  • Fiona Britton

  • Jessica Coyle

  • Kathleen Connors

  • Neethu Billy Graham Mariam

  • Jamie Weaver

  • Tom Waddell

  • Richard Hubner

  • Konstantinos Kamposioras

  • Wasat Mansoor

Medical Centers

  • The Royal Hallamshire Hospital, Sheffield Teaching Hospitals, NHS Foundation Trust, Sheffield, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Fluorouracil

  • Adrucil injection

  • Oxaliplatin

  • leucovorin

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved